Close Menu

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    Etihad to fly daily between Abu Dhabi and Calgary from 2027

    November 17, 2026

    Google links Gemini to Wallet for spending and budget help

    November 16, 2026

    FAA grounds US flights nationwide over communications outage

    November 14, 2026
    Montreal 24×7Montreal 24×7
    • Automotive

      Jaguar Type 01 electric GT debuts with 1,030 PS

      October 7, 2026

      Canada EV sales rebound while Saskatchewan lags

      June 22, 2026

      Nissan develops new self-driving system for urban streets

      September 22, 2025

      Dashboard display fault prompts Toyota recall of 70K vehicles in Canada

      September 20, 2025

      Tesla’s Europe sales drop continues for seventh straight month

      August 28, 2025
    • Business

      Oil rebounds from two-month low as Hormuz risks linger

      November 12, 2026

      Canada budget plans C$25 billion sovereign wealth fund

      November 7, 2026

      Google launches AI checkout in Canada through Gemini

      November 5, 2026

      B.C. ostrich farm sues Ottawa over $200M supplement loss

      November 4, 2026

      AI lifts Meta ad growth to 26% as Google search slows

      November 2, 2026
    • Entertainment

      Critics say Ben Affleck understates AI use in film and TV

      January 27, 2026

      Disney’s Fantastic Four beats Superman in box office debut

      July 27, 2025

      Disney and Marvel’s R-rated film hits billion-dollar milestone

      August 17, 2024

      Web3 leader Immutable rolls out $50M gaming rewards initiative

      April 27, 2024

      USHER’s pre-Super Bowl experience on Apple Music

      February 7, 2024
    • Health

      Health Experts Warn of Respiratory Risks and Future Smoking Among Youth Vapers, Urge Regulatory Action

      August 21, 2026

      World Cup host nations align Ebola border measures

      May 30, 2026

      Canada set for generic weight-loss drug arrivals this summer

      March 31, 2026

      Study explains exceptional memory in some people over 80

      January 15, 2026

      Stanford researchers restore cartilage in aging joint models

      January 12, 2026
    • Lifestyle

      JP Morgan funds Fresha with $31 million for AI and robotics growth

      August 23, 2024

      Adidas, Highsnobiety debut limited-edition sneakers

      January 6, 2024

      Unraveling Starbucks’ phenomenon as a worldwide coffee powerhouse

      September 1, 2023

      How Nike’s Kobe 8 Protro Halo Marks an Emotional Milestone

      August 29, 2023

      From labels to legacy – understanding fashion’s hierarchy

      August 21, 2023
    • Luxury

      Price hikes and lack of innovation erode luxury market confidence

      November 18, 2024

      Uncover the allure of Rolex Deepsea – luxury awaits.

      April 10, 2024

      Beyond timekeeping to the prestige of the Rolex Day-Date

      March 2, 2024

      Rare uncut emerald dazzles at Sharjah show

      February 1, 2024

      Porsche and Frauscher launch the electric 850 Fantom Air

      October 17, 2023
    • News

      FAA grounds US flights nationwide over communications outage

      November 14, 2026

      Mice push Halifax hospital pest-control bills up nearly 800%

      November 13, 2026

      B.C. braces for more than 250 mm of rain as storm hits

      November 11, 2026

      Austria calls for stronger EU-Canada partnership in Ottawa

      November 9, 2026

      UN climate chief urges real-world progress at COP31 in Antalya

      November 6, 2026
    • Sports

      Canada move on after 1-0 World Cup win over South Africa

      June 29, 2026

      Portugal held by DR Congo in 1-1 World Cup opener

      June 18, 2026

      Argentina beat Algeria as Messi equals World Cup goal record

      June 17, 2026

      Mbappe double lifts France past Senegal at World Cup

      June 17, 2026

      Germany beats Curaçao 7-1 to open World Cup 2026

      June 16, 2026
    • Technology

      Google links Gemini to Wallet for spending and budget help

      November 16, 2026

      Apple iPhone Duo sets new benchmark for foldable smartphones

      November 2, 2026

      iPhone Duo review: Apple’s first foldable balances trade-offs

      November 2, 2026

      Apple unveils MacBook Pro with OLED display and touch

      October 29, 2026

      Integrated Identity Enters Global Top 0.1% with Rare 100/100 Google PageSpeed

      October 29, 2026
    • Travel

      Etihad to fly daily between Abu Dhabi and Calgary from 2027

      November 17, 2026

      Ontario to Lift Travel Restrictions and Fire Zone, Authorities Announce

      August 21, 2026

      Canada cross border trips to U.S. fell sharply in late 2025

      January 28, 2026

      US immigration screening review suspends Pakistan exempts India

      January 15, 2026

      Canada reassures American tourists while U.S. regions scale back Canada marketing

      January 14, 2026
    Montreal 24×7Montreal 24×7
    Home » InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Reports Phase 2 Trial Progress for NV-387 in Ebola and Mpox Treatments
    IBN

    InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Reports Phase 2 Trial Progress for NV-387 in Ebola and Mpox Treatments

    November 17, 2026

    NanoViricides, Inc. (NYSE American: NNVC) announced the filing of its quarterly report on Form 10-Q for the fiscal quarter ended Sept. 30, 2026, highlighting the advancement of its broad-spectrum antiviral candidate NV-387 Oral Gummies into two Phase 2 clinical trials. Enrollment began Sept. 23 for a trial evaluating NV-387 against Ebola Bundibugyo virus disease in the Democratic Republic of the Congo, while a separate Phase 2 trial site opened the same day to evaluate the treatment for mpox. The company said it has funded the Ebola trial independently and established clinical testing infrastructure, including on-site molecular diagnostic capabilities, to support its research.

    NanoViricides also highlighted U.S. Food and Drug Administration (“FDA”) Orphan Drug and Rare Pediatric Disease designations granted to NV-387 for measles treatment in April and May 2026, respectively. The company plans to pursue a Phase 2 measles trial and seek nondilutive funding, including potential U.S. government grants, to advance development. NV-387 remains investigational, with its effectiveness for these indications under clinical evaluation.

    To view the full press release, visit https://ibn.fm/HChFn

    About NanoViricides

    NanoViricides, Inc. (the “Company”) (www.nanoviricides.com) is a clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company’s novel nanoviricide(TM) class of drug candidates and the nanoviricide(TM) technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments.

    The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The Company’s business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.

    Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections, and even Measles. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical trials.

    NV-CoV-2 (API NV-387) is our nanoviricide drug candidate for COVID-19 that does not encapsulate remdesivir. NV-CoV-2-R is our other drug candidate for COVID-19 that is made up of NV-387 with remdesivir encapsulated within its polymeric micelles. The Company believes that since remdesivir is already US FDA approved, our drug candidate encapsulating remdesivir is likely to be an approvable drug, if safety is comparable. Remdesivir is developed by Gilead. The Company has developed both of its own drug candidates NV-CoV-2 and NV-CoV-2-R independently.

    The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides’ platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful. As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company’s pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product.

    NOTE TO INVESTORS: The latest news and updates relating to NNVC are available in the company’s newsroom at https://ibn.fm/NNVC

    About InvestorWire

    InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

    For more information, please visit https://www.InvestorWire.com

    Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

    InvestorWire
    Austin, Texas
    www.InvestorWire.com
    512.354.7000 Office
    Editor@InvestorWire.com

    InvestorWire is powered by IBN

    Share. Facebook Twitter Pinterest WhatsApp

    Related Posts

    AINewsBreaks – Nightfood Holdings Inc. (OTCQB: NGTFD) Featured in AINewsWire Editorial on AI Infrastructure and Semiconductor Equipment Growth

    November 17, 2026

    InvestorNewsBreaks – Metalsource Mining Inc. (CSE: MSM) (OTCQB: MSMMF) (FSE: E9Z) Featured in MiningNewsWire Editorial on Gold, Silver and Critical Minerals Investment Opportunities

    November 17, 2026

    InvestorNewsBreaks – Mobilicom Limited (NASDAQ: MOB) Secures $863,000 Follow-On Defense Order, Bringing Program Total to $4.7 Million

    November 17, 2026

    TinyGemsBreaks – ZenaTech, Inc. (NASDAQ: ZENA) (FSE: 49Q) (BMV: ZENA) Secures Energy Sector Survey Contracts With Potential Follow-On Work Totaling Nearly C$1 Million

    November 17, 2026

    TechMediaBreaks – Safe Pro Group Inc. (NASDAQ: SPAI) Highlights Upcoming GT Scout Launch and Record Q3 Results in Shareholder Letter

    November 17, 2026

    BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Receives USPTO Notice of Allowance for Abuse-Deterrent Fentanyl Patch Brand Names

    November 17, 2026
    Latest News

    Etihad to fly daily between Abu Dhabi and Calgary from 2027

    November 17, 2026

    – Etihad Airways will increase its Abu Dhabi-Calgary service from four weekly flights to daily operations starting October 15, 2027. The airline announced the plan just three weeks after launching the route, citing strong early bookings and fully booked inaugural

    Google links Gemini to Wallet for spending and budget help

    November 16, 2026

    – Google has announced that users can connect its Gemini AI assistant to Google Wallet to analyze spending, prepare budgets and track recurring subscriptions. The tools work directly through the Gemini chat interface. The feature has begun rolling out in

    Entertainment

    Critics say Ben Affleck understates AI use in film and TV

    January 27, 2026

    Disney’s Fantastic Four beats Superman in box office debut

    July 27, 2025

    Disney and Marvel’s R-rated film hits billion-dollar milestone

    August 17, 2024

    Web3 leader Immutable rolls out $50M gaming rewards initiative

    April 27, 2024
    Business

    Oil rebounds from two-month low as Hormuz risks linger

    November 12, 2026

    Canada budget plans C$25 billion sovereign wealth fund

    November 7, 2026

    Google launches AI checkout in Canada through Gemini

    November 5, 2026

    B.C. ostrich farm sues Ottawa over $200M supplement loss

    November 4, 2026
    Automotive

    Jaguar Type 01 electric GT debuts with 1,030 PS

    October 7, 2026

    Canada EV sales rebound while Saskatchewan lags

    June 22, 2026

    Nissan develops new self-driving system for urban streets

    September 22, 2025

    Dashboard display fault prompts Toyota recall of 70K vehicles in Canada

    September 20, 2025
    © 2026 Montreal 24x7 | All Rights Reserved
    • Home
    • Contact Us
    • Disclaimer

    Type above and press Enter to search. Press Esc to cancel.